Genetics of inflammatory bowel diseases - Past, present, and future

Digestive Diseases

Volumn 21, Issue 2, 2003, Pages 85-90

  Pena A S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Candidate gene approach; Crohn's disease; Genetic epidemiology; Genetics; Genome wide screening; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

IMMUNOMODULATING AGENT;

CHRONIC INFLAMMATION; DRUG EFFICACY; ENTERITIS; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENOME; HUMAN; IMMUNITY; IMMUNOMODULATION; MEDICAL INFORMATION; MEDICAL RESEARCH; MULTIFACTORIAL GENETIC DISORDER; PRIORITY JOURNAL; REVIEW; SCIENCE;

GENETIC PREDISPOSITION TO DISEASE; GENOME; HUMANS; IMMUNE SYSTEM; INCIDENCE; INFLAMMATORY BOWEL DISEASES;

EID: 0142249902     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073241     Document Type: Review

References (39)

1. Oudkerk Pool M, Bouma G, Meuwissen SG, von Blomberg BM, van de Merwe JP, Deville WL, et al: Serological markers to differentiate between ulcerative colitis and Crohn's disease. J Clin Pathol 1995;48:346-350.
2. Panaccione R, Sandborn WJ: Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology 1999;116:1001-1002.
3. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR: Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-496.
4. Bartunkova J, Kolarova I, Sediva A, Holzelova E: Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. Clin Immunol 2002;102:162-168.
5. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, et al: The value of serologic markers in indeterminate colitis: A prospective follow-up study. Gastroenterology 2002;122:1242-1247.
6. Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, et al: Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002;97:1458-1462.
7. Glas J, Torok HP, Vilsmaier F, Herbinger KH, Hoelscher M, Folwaczny C: Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: Potential clinical value. Digestion 2002;66:173-177.
8. Linskens RK, Mallant-Hent RC, GroothuisMink ZM, Bakker-Jonges LE, van de Merwe JP, Hooijkaas H, et al: Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol 2002;14:1013-1018.
9. Reumaux D, Sendid B, Poulain D, Duthilleul P, Dewit O, Colombel JF: Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2003;17:19-35.
10. Bouma G, Poen AC, Garcia-Gonzalez MA, Schreuder GMT, Felt-Bersma RJF, Meuwissen SGM, et al: HLA-DRB1*03, but not the TNFA-308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. Immunogenetics 1998;47:451-455.
11. van Heel DA, Satsangi J, Carey AH, Jewell DP: Inflammatory bowel disease: progress toward a gene. Can J Gastroenterol 2000;14:207-218.
12. Bogunia-Kubik K, Tomeczko J, Suchnicki K, Lange A: HLA-DRB1*03, DRB1*11 or DRB1*12 and their respective DRB3 specificities in clinical variants of sarcoidosis. Tissue Antigens 2001;57:87-90.
13. Tzioufas AG, Wassmuth R, Dafni UG, Guialis A, Haga HJ, Isenberg DA, et al: Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): A European multi-centre study. Ann Rheum Dis 2002;61:398-404.
14. Timmer A, Sutherland LR: Identifying Crohn's disease patients with a high risk of relapse. Res Clin Forums 1988;20:77-86.
15. Tabor HK, Risch NJ, Myers RM: Opinion: Candidate-gene approaches for studying complex genetic traits: Practical considerations. Nat Rev Genet 2002;3:391-397.
16. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
17. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606.
18. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, et al: Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-1928.
19. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK: CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000.
20. Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig GH, Seegert D, et al: TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003;124:1001-1009.
21. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-191.
22. Okayama N, Fujimura K, Suehiro Y, Hamanaka Y, Fujiwara M, Matsubara T, et al: Simple genotype analysis of the Asp299Gly polymorphism of the Toll-like receptor-4 gene that is associated with lipopolysaccharide hyporesponsiveness. J Clin Lab Anal 2002;16:56-58.
23. Sugimura K, Taylor KD, Lin YC, Hang T, Wang D, Tang YM, et al: A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet 2003;72:509-518.
24. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, et al: Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002;123:86-91.
25. Yamazaki K, Takazoe M, Tanaka T, Kazumori T, Nakamura Y: Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet 2002;47:469-472.
26. Croucher PJ, Mascheretti S, Hampe J, Huse K, Frenzel H, Stoll M, et al: Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 2003;11:6-16.
27. Roussomoustakaki M, Koutroubakis I, Vardas EM, Dimoulios P, Kouroumalis EA, Baritaki S, et al: NOD2 insertion mutation in a Cretan Crohn's disease population. Gastroenterology 2003;124:272-273.
28. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-787.
29. Cario E, Podolsky DK: Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7017.
30. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al: A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
31. Beutler B: Autoimmunity and apoptosis: The Crohn's connection. Immunity 2001;15:5-14.
32. Hecht G: Innate mechanisms of epithelial host defense: Spotlight on intestine. Am J Physiol 1999;277:C351-358.
33. Cho JH: The Nod2 gene in Crohn's disease: Implications for future research into the genetics and immunology of Crohn's disease. Inflamm Bowel Dis 2001;7:271-275.
34. Miettinen M, Lehtonen A, Julkunen I, Matikainen S: Lactobacilli and Streptococci activate NF-kappa B and STAT signaling pathways in human macrophages. J Immunol 2000;164:3733-3740.
35. Korhonen R, Korpela R, Saxelin M, Maki M, Kankaanranta H, Moilanen E: Induction of nitric oxide synthesis by probiotic Lactobacillus rhamnosus GG in J774 macrophages and human T84 intestinal epithelial cells. Inflammation 2001;25:223-232.
36. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M: The two faces of IKK and NF-kappaB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003;9:575-581.
37. Inohara N, Koseki T, del Peso L, Hu Y, Yee C, Chen S, et al: Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappa B. J Biol Chem 1999;274:14560-14567.
38. Inohara N, Nunez G: The NOD: A signaling module that regulates apoptosis and host defense against pathogens. Oncogene 2001;20:6473-6481.
39. Burn J, Duff G, Holtzman N: Three views of genetics: the enthusiast, the visionary, and the sceptic. Interview by Tessa Richards. BMJ 2001;322:1016.